A Phase III, randomized, open-label, multicenter trial evaluating the non-inferiority of raltegravir compared with efavirenz, in combination with tenofovir and lamivudine, in antiretroviral-naive individuals infected with HIV-1 receiving rifampin for active tuberculosis.
A Phase III, randomized, open-label, multicenter trial evaluating the non-inferiority of raltegravir compared with efavirenz, in combination with tenofovir and lamivudine, in antiretroviral-naive individuals infected with HIV-1 receiving rifampin for active tuberculosis.
Project Details
Participating Countries
- • Brazil
- • Ivory Coast
- • France
- • Vietnam
Description & Context
Research Team
The research team has not yet been filled in for this project.
Collaborate with us
We are open to partnerships with international research institutions and doctoral students.
Estimated response time: 3-5 business days.
